cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Corcept Therapeutics Inc
8 own
8 watching
Current Price
$23.13
$0.68
(3.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,660.82M
52-Week High
52-Week High
34.28000
52-Week Low
52-Week Low
17.86000
Average Volume
Average Volume
0.97M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
24.3094
iconMarket Capitalization2,660.82M
icon52-Week High34.28000
icon52-Week Low17.86000
iconAverage Volume0.97M
iconDividend Yield--
iconP/E Ratio24.3094
What does the Corcept Therapeutics Inc do?
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Read More
How much money does Corcept Therapeutics Inc make?
News & Events about Corcept Therapeutics Inc.
Ticker Report
8 months ago
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT Get Rating) have been assigned an average recommendation of Hold from the seven ratings firms that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold ...
Globe Newswire
11 months ago
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (Corcept), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects ...
Globe Newswire
1 year ago
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ...
Globe Newswire
1 year ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible...
Business Wire
1 year ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company...
Frequently Asked Questions
Frequently Asked Questions
What is Corcept Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Corcept Therapeutics Inc shares?
plus_minus_icon
How can I buy Corcept Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Corcept Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Corcept Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Corcept Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Corcept Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Corcept Therapeutics Inc?
plus_minus_icon
What percentage is Corcept Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Corcept Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.13
$0.68
(3.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00